Morepen Laboratories · NSE: MOREPENLAB · BSE: 500288
Q1 FY22 results · Apr–Jun 2021
Morepen Laboratories reported revenue from operations of ₹386.73 crore (up 50.1% from Q1 FY21) and net profit of ₹30.47 crore (up 57.3% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 386.73 | 257.64 | +50.1% | 286.60 | +34.9% |
| Other income | 1.58 | 1.33 | +19.1% | 4.16 | −62.0% |
| Total income | 388.31 | 258.97 | +49.9% | 290.76 | +33.6% |
| Profit before tax | 38.53 | 19.55 | +97.0% | 27.63 | +39.4% |
| Net profit for the period | 30.47 | 19.37 | +57.3% | 26.76 | +13.9% |
| EPS, basic (₹) | 0.68 | 0.43 | +58.1% | 0.59 | +15.3% |
| Net margin (%) | 7.9 | 7.5 | 9.3 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 365.23 | 243.26 | +50.1% | 264.11 | +38.3% |
| Other income | 1.58 | 1.33 | +19.1% | 3.87 | −59.1% |
| Total income | 366.81 | 244.59 | +50.0% | 267.97 | +36.9% |
| Profit before tax | 38.62 | 18.85 | +104.9% | 25.14 | +53.6% |
| Net profit for the period | 30.85 | 18.85 | +63.7% | 25.14 | +22.7% |
| EPS, basic (₹) | 0.69 | 0.42 | +64.3% | 0.56 | +23.2% |
| Net margin (%) | 8.4 | 7.7 | 9.5 |
Consolidated
- Filed with BSE
- 28 Jul 2021, 08:47 IST
- Board meeting
- 27 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2021, 08:47 IST
- Board meeting
- 27 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE